Novavax | NVAX - Pre Tax Profit


Novavax reported $17.9M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Adma Biologics USD 61.59M 14.07M Dec/2025
Agenus USD -10.61M 263.52M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Geron USD -3.64M 27.5M Mar/2026
GlaxoSmithKline GBP 2.14B 919M Mar/2026
MannKind USD -16.37M 4.56M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Moderna USD -799M 612M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
TG Therapeutics USD 20.36M 24.73M Mar/2026